• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Sotera Health Appoints Karen Flynn to Board of Directors

    11/13/23 7:00:14 AM ET
    $CTLT
    $QTRX
    $SHC
    $WST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $CTLT alert in real time by email

    CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board.

    Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer health products. Prior to this, she held the positions of Chief Commercial Officer and President of Biologics at Catalent. Prior to Catalent, she served as Senior Vice President and Chief Commercial Officer for West Pharmaceutical Services (NYSE:WST), and as President of its Pharmaceutical Packaging Systems business. In addition to her experience leading high-growth businesses, Ms. Flynn brings an extensive background in commercial strategy, strategic planning and innovation and quality management.

    "We are excited to welcome Karen to our Board of Directors," said Michael B. Petras, Jr., Chairman and Chief Executive Officer of Sotera Health. "Karen's extensive commercial expertise in pharmaceutical services will serve as a tremendous asset as we continue to grow. Additionally, her strong Board leadership and governance experience will be valuable as we advance as a public company."

    Ms. Flynn currently serves on the Board of Directors of Quanterix Corporation (NASDAQ:QTRX), where she is a member of the Compensation and Nominating and Governance Committees and on the Board of Directors of Catalent. She has also served on the Board of Recro Pharma, Inc., a specialty pharma and contract development and manufacturing organization, where she was Chair of the Compensation Committee and a member of the Audit Committee.

    Ms. Flynn holds a Master of Science in Engineering from University of Pennsylvania and a Master of Science in Business Administration from Boston University. She completed her Bachelor of Science at the University of Notre Dame.

    About Sotera Health

    Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

    Contacts

    Jason Peterson

    Vice President & Treasurer, Sotera Health

    [email protected]

    Kristin Gibbs

    Chief Marketing Officer, Sotera Health

    [email protected]

    Source: Sotera Health Company



    Primary Logo

    Get the next $CTLT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTLT
    $QTRX
    $SHC
    $WST

    CompanyDatePrice TargetRatingAnalyst
    Sotera Health Company
    $SHC
    5/5/2025$17.00Neutral → Buy
    Goldman
    West Pharmaceutical Services Inc.
    $WST
    3/18/2025$275.00Outperform
    Evercore ISI
    West Pharmaceutical Services Inc.
    $WST
    2/14/2025$250.00Hold → Buy
    Deutsche Bank
    West Pharmaceutical Services Inc.
    $WST
    1/8/2025$400.00Buy
    Citigroup
    West Pharmaceutical Services Inc.
    $WST
    12/13/2024Peer Perform
    Wolfe Research
    West Pharmaceutical Services Inc.
    $WST
    12/12/2024$350.00 → $390.00Neutral → Buy
    UBS
    Sotera Health Company
    $SHC
    12/6/2024$14.00Neutral
    Goldman
    Sotera Health Company
    $SHC
    5/21/2024$13.00Neutral
    Piper Sandler
    More analyst ratings

    $CTLT
    $QTRX
    $SHC
    $WST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sotera Health Company

      SC 13G/A - Sotera Health Co (0001822479) (Subject)

      11/14/24 4:51:55 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sotera Health Company

      SC 13G/A - Sotera Health Co (0001822479) (Subject)

      11/14/24 4:50:09 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Catalent Inc.

      SC 13G/A - Catalent, Inc. (0001596783) (Subject)

      11/14/24 4:35:03 PM ET
      $CTLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTLT
    $QTRX
    $SHC
    $WST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sotera Health upgraded by Goldman with a new price target

      Goldman upgraded Sotera Health from Neutral to Buy and set a new price target of $17.00

      5/5/25 8:27:32 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Evercore ISI initiated coverage on West Pharm with a new price target

      Evercore ISI initiated coverage of West Pharm with a rating of Outperform and set a new price target of $275.00

      3/18/25 7:58:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Pharm upgraded by Deutsche Bank with a new price target

      Deutsche Bank upgraded West Pharm from Hold to Buy and set a new price target of $250.00

      2/14/25 7:09:40 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $CTLT
    $QTRX
    $SHC
    $WST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Michels Douglas A was granted 1,071 shares, increasing direct ownership by 2% to 45,171 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 5:04:01 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Director Pucci Paolo was granted 1,071 shares, increasing direct ownership by 11% to 10,947 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 5:00:01 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Director Haugen Janet Brutschea was granted 1,071 shares, increasing direct ownership by 433% to 1,318 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 4:54:17 PM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $CTLT
    $QTRX
    $SHC
    $WST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • West to Participate in Upcoming Investor Conferences

      EXTON, Pa., May 7, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the BofA Securities Annual Healthcare Conference on Wednesday, May 14, 2025 at 2:20 PM PT. It will also present at the William Blair 45th Annual Growth Stock Conference on Thursday, June 5, 2025 at 10:40 AM CT. A live audio webcast of these events will be available in the "Investors" section of the Company's website at www.westpharma.com. Replay of the webcasts will be availabl

      5/7/25 4:30:00 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, May 12, 2025, at 4:30 p.m. E.T., to discuss its first quarter 2025 financial results. Quanterix will issue a press release regarding its first quarter 2025 financial results prior to the conference call on Monday, May 12, 2025, after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/. To listen to the live conference call, investors can dial (800) 715-9871 or (646) 307-1963 and enter conference ID 7353673. Interested investors can also access the live we

      5/5/25 7:00:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Sotera Health Reports First-Quarter 2025 Results

      Q1 2025 net revenues increased 2.6% to $255 million, compared to Q1 2024, or 4.4% on a constant currency basisQ1 2025 net loss of $13 million or $0.05 per diluted share, compared to net income of $6 million or $0.02 per diluted share in Q1 2024Q1 2025 Adjusted EBITDA(1) increased 8.8% to $122 million, compared to Q1 2024, or 11.2% on a constant currency basisQ1 2025 Adjusted EPS(1) of $0.14, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.13 in Q1 2024Company reaffirms full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("

      5/1/25 7:38:53 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    $CTLT
    $QTRX
    $SHC
    $WST
    Leadership Updates

    Live Leadership Updates

    See more
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Catalent Announces New Board Appointments

      Adds three new directors with deep expertise across biopharma and life sciences Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings' ownership. Alessandro Maselli, President and CEO, and Board member of Catalent, said "I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech customers. Susan, Marie-France and Tim are each accomplished leaders who bring

      2/20/25 9:00:00 AM ET
      $CTLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

      CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company's Board of Directors since 2020, brings a wealth of experience and a deep understanding of the Company's strategic vision and operations. In this newly appointed role, Mr. Petrella will serve as a key liaison among the Board, management and shareholders. Mr. Petrella has decades of

      1/6/25 4:30:38 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    $CTLT
    $QTRX
    $SHC
    $WST
    Financials

    Live finance-specific insights

    See more
    • Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, May 12, 2025, at 4:30 p.m. E.T., to discuss its first quarter 2025 financial results. Quanterix will issue a press release regarding its first quarter 2025 financial results prior to the conference call on Monday, May 12, 2025, after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/. To listen to the live conference call, investors can dial (800) 715-9871 or (646) 307-1963 and enter conference ID 7353673. Interested investors can also access the live we

      5/5/25 7:00:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Sotera Health Reports First-Quarter 2025 Results

      Q1 2025 net revenues increased 2.6% to $255 million, compared to Q1 2024, or 4.4% on a constant currency basisQ1 2025 net loss of $13 million or $0.05 per diluted share, compared to net income of $6 million or $0.02 per diluted share in Q1 2024Q1 2025 Adjusted EBITDA(1) increased 8.8% to $122 million, compared to Q1 2024, or 11.2% on a constant currency basisQ1 2025 Adjusted EPS(1) of $0.14, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.13 in Q1 2024Company reaffirms full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("

      5/1/25 7:38:53 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • West Announces Leadership Changes

      Bernard J. Birkett Announces Intention to Retire from West, Company Initiates Search for a Successor Shane Campbell Appointed Senior Vice President, Chief Proprietary Segment Officer EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced executive leadership changes as part of its succession planning process. Bernard J. Birkett, Senior Vice President, Chief Financial Officer, informed West of his intention to step down from his current position this ye

      4/24/25 6:10:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $CTLT
    $QTRX
    $SHC
    $WST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Walt David R bought $624,630 worth of shares (47,000 units at $13.29) and gifted 2,000 shares, increasing direct ownership by 3% to 1,487,342 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      9/17/24 4:35:10 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President & CEO Toloue Masoud bought $207,100 worth of shares (19,000 units at $10.90), increasing direct ownership by 6% to 354,119 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      8/15/24 4:03:35 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTLT
    $QTRX
    $SHC
    $WST
    SEC Filings

    See more
    • West Pharmaceutical Services Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      5/8/25 4:46:47 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Quanterix Corporation

      SCHEDULE 13G/A - Quanterix Corp (0001503274) (Subject)

      5/7/25 10:44:05 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Sotera Health Company

      DEFA14A - Sotera Health Co (0001822479) (Filer)

      5/2/25 4:05:40 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care